{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T02:10:01Z","timestamp":1748398201376,"version":"3.41.0"},"reference-count":18,"publisher":"Colegio Mexicano de Inmunologia Clinica y Alergia, A. C.","issue":"4","license":[{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev Alerg Mex"],"abstract":"<jats:p>Objective: to perform a cost-effectiveness analysis of asthma treatment with budesonide\/formoterol against other treatment options used at Mexico\u2019s National Institute for Respiratory Diseases.\nMethods: A complete economic evaluation of cost-effectiveness from a public health perspective, comparing the use of budesonide\/formoterol as maintenance therapy with fluticasone\/vilanterol in 103 female asthma patients managed at INER between 2015 and 2021.\nResults: Average cost per patient was $743.23 USD, $733.36 USD for budesonide\/formoterol and $767.24 USD for fluticasone\/vilanterol. Pharmacological treatment represented over 70% of management costs for both groups, followed by follow-up visits and exacerbation management costs. LABA-ICS represented the highest proportion of pharmacologic management costs with a statistically significant difference amongst groups with an incremental cost of $80.17 USD for the fluticasone\/vilanterol group. The budesonide\/formoterol group showed an ICER of $613.31 USD for reducing the proportion of patients experiencing exacerbations during follow-up. Considering the willingness to pay threshold based on one GDP per capita ($10,902.98 USD in 2022), budesonide\/formoterol represented a very cost-effective option.\nConclusions: The ICER favored budesonide\/formoterol over fluticasone\/vilanterol in terms of cost-effectiveness. A 5.5% reduction in patient exacerbations indicated decreased disease burden. While not statistically significant, fewer exacerbations per patient might still cut costs by lowering emergency visits and hospitalizations.\nKeywords: Cost-effectiveness analysis; Asthma; Budesonide; Formoterol fumarate.<\/jats:p>","DOI":"10.29262\/ram.v71i4.1295","type":"journal-article","created":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T02:59:03Z","timestamp":1735268343000},"page":"218-228","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness of budesonide-formoterol in maintenance therapy of asthma patients at Mexico\u2019s National Center for Respiratory Diseases.","Costo-efectividad de budesonida-formoterol en el tratamiento de mantenimiento en pacientes con asma"],"prefix":"10.29262","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3954-1368","authenticated-orcid":false,"given":"Mar\u00eda del Carmen Cano-Salas","family":"Cano Salas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4071-3254","authenticated-orcid":false,"family":"Jos\u00e9 L. Miguel-Reyes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Erika C. L\u00f3pez-Estrada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Jorge Salas-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monserrat E","family":"Arroyo-Rojas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Mauricio Casta\u00f1eda-Valdivia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Monserrat Escobar-Preciado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Homero Garc\u00e9s-Flores","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Silvia Guzm\u00e1n- V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Sergio R. Garc\u00eda-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Herman Soto-Molina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11808","published-online":{"date-parts":[[2024,12,30]]},"reference":[{"key":"59742","doi-asserted-by":"publisher","DOI":"10.29262\/ram.v64i2.256"},{"key":"59743","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.05.033"},{"key":"59744","doi-asserted-by":"publisher","DOI":"10.3109\/02770903.2014.999283"},{"key":"59745","unstructured":"Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention; 2022. www.ginasthma.org"},{"key":"59746","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.10.003"},{"key":"59747","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.01.00065801"},{"key":"59748","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802567566"},{"key":"59749","doi-asserted-by":"publisher","DOI":"10.1007\/BF03321485"},{"key":"59750","unstructured":"Consejo de Salubridad General. Gu\u00eda de Evaluaci\u00f3n de Insumos para la Salud [Internet]. M\u00e9xico; 2023. http:\/\/www.csg.gob.mx\/descargas\/pdf\/priorizacion\/cuadro-basico\/guias\/insumos_salud\/GEI_Enero_2023.pdf"},{"key":"59751","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g3009"},{"key":"59752","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.10.024"},{"key":"59753","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.01.039"},{"key":"59754","doi-asserted-by":"publisher","DOI":"10.1186\/s40733-015-0016-0"},{"key":"59755","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2016.01.005"},{"key":"59756","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2005.09.032"},{"key":"59757","doi-asserted-by":"publisher","DOI":"10.1053\/rmed.2001.1078"},{"key":"59758","unstructured":"J\u00f6nsson BG, Berggren FE, Svensson K, O'Byrne PM. Budesonide and formoterol in mild persistent asthma compared with doubling the dose of budesonide - a cost-effectiveness analysis. Eur Respir J 2001; 16 (Suppl 31): 3487."},{"key":"59759","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2003.tb10584.x"}],"container-title":["Revista Alergia M\u00e9xico"],"original-title":[],"link":[{"URL":"https:\/\/www.revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/1295\/2241","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/1295\/2499","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/1295\/2241","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T01:35:46Z","timestamp":1748396146000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.revistaalergia.mx\/ojs\/index.php\/ram\/article\/view\/1295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":18,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,12,26]]}},"URL":"https:\/\/doi.org\/10.29262\/ram.v71i4.1295","relation":{},"ISSN":["2448-9190","0002-5151"],"issn-type":[{"type":"electronic","value":"2448-9190"},{"type":"print","value":"0002-5151"}],"subject":[],"published":{"date-parts":[[2024,12,30]]}}}